Advertisement

Drugs

, Volume 79, Issue 9, pp 997–1008 | Cite as

Tiotropium/Olodaterol: A Review in COPD

  • Hannah A. BlairEmail author
Adis Drug Evaluation
  • 182 Downloads

Abstract

Tiotropium/olodaterol (Stiolto® Respimat®; Spiolto® Respimat®) is an inhaled fixed-dose combination of the long-acting muscarinic antagonist tiotropium bromide (hereafter referred to as tiotropium) and the long-acting β2-adrenergic agonist olodaterol. It is available in several countries, including the USA, Japan, China and those of the EU, where it is indicated for the long-term maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). The efficacy of tiotropium/olodaterol 5/5 μg/day in patients with COPD was evaluated in phase III or IV trials of 6–52 weeks’ duration. Tiotropium/olodaterol improved lung function to a greater extent than each of its individual components or placebo in 12- and 52-week trials. In 6-week trials, tiotropium/olodaterol provided greater lung function benefits over 24 h than the individual components, placebo or twice-daily fluticasone propionate/salmeterol. Tiotropium/olodaterol also demonstrated beneficial effects on health-related quality of life (HR-QoL), dyspnoea, inspiratory capacity, exercise endurance and the need for rescue medication. In an 8-week open-label trial, umeclidinium/vilanterol was superior to tiotropium/olodaterol for the primary endpoint of trough forced expiratory volume in 1 s. The tolerability profile of tiotropium/olodaterol was generally similar to that of the individual components. In conclusion, tiotropium/olodaterol provides a useful option for the maintenance treatment of COPD, with the convenience of once-daily administration via a single inhaler.

Notes

Acknowledgements

During the review process, the manufacturer of tiotropium/olodaterol was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

Hannah Blair is a salaried employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.

References

  1. 1.
    Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2019. http://goldcopd.org/gold-reports/. Accessed 7 May 2019.
  2. 2.
    Boehringer Ingelheim. Stiolto® Respimat® (tiotropium bromide and olodaterol): US prescribing information; 2018. http://www.fda.gov. Accessed 7 May 2019.
  3. 3.
    Pharmaceuticals and Medical Devices Agency. Spiolto Respimat 28 puffs / Spiolto Respimat 60 puffs: Japanese prescribing information; 2015. http://www.pmda.go.jp. Accessed 7 May 2019.
  4. 4.
    National Drug Administration Drug Evaluation Center. Tiotropium bromide olodaterol inhalation spray: Chinese prescribing information; 2018. http://202.96.26.102/. Accessed 7 May 2019.
  5. 5.
    European Medicines Agency. Spiolto® Respimat® (tiotropium bromide and olodaterol): summary of product characteristics; 2018. http://www.ema.europa.eu. Accessed 7 May 2019.
  6. 6.
    Deeks ED. Olodaterol: a review of its use in chronic obstructive pulmonary disease. Drugs. 2015;75(6):665–73.Google Scholar
  7. 7.
    Keating GM. Tiotropium Respimat® Soft Mist™ inhaler: a review of its use in chronic obstructive pulmonary disease. Drugs. 2014;74(15):1801–16.Google Scholar
  8. 8.
    Dhillon S. Tiotropium/olodaterol: a review in COPD. Drugs. 2016;76(1):135–46.Google Scholar
  9. 9.
    Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4). Eur Respir J. 2015;45(4):969–79.Google Scholar
  10. 10.
    Singh D, Ferguson GT, Bolitschek J, et al. Tiotropium plus olodaterol shows clinically meaningful improvements in quality of life. Respir Med. 2015;109(10):1312–9.Google Scholar
  11. 11.
    Beeh KM, Westerman J, Kirsten AM, et al. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2015;32:53–9.Google Scholar
  12. 12.
    Beeh KM, Derom E, Echave-Sustaeta J, et al. The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler® (ENERGITO® study). Int J Chron Obstruct Pulmon Dis. 2016;11(1):193–205.Google Scholar
  13. 13.
    Calverley PMA, Anzueto AR, Carter K, et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. Lancet Respir Med. 2018;6(5):337–44.Google Scholar
  14. 14.
    O’Donnell DE, Casaburi R, Frith P, et al. Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD. Eur Respir J. 2017;49(4):1601348.Google Scholar
  15. 15.
    Maltais F, O’Donnell D, Galdiz Iturri JB, et al. Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2018;12:1–13.Google Scholar
  16. 16.
    Troosters T, Maltais F, Leidy N, et al. Effect of bronchodilation, exercise training, and behavior modification on symptoms and physical activity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198(8):1021–32.Google Scholar
  17. 17.
    Maltais F, Aumann JL, Kirsten AM, et al. Dual bronchodilation with tiotropium/olodaterol further reduces activity-related breathlessness versus tiotropium alone in COPD. Eur Respir J. 2019.  https://doi.org/10.1183/13993003.02049-2018.Google Scholar
  18. 18.
    Ferguson GT, Karpel JP, Clerisme-Beaty E, et al. Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO® and OTEMTO® studies: a subgroup analysis by age. Int J Chron Obstruct Pulmon Dis. 2016;11(1):2701–10.Google Scholar
  19. 19.
    Ferguson GT, Flezar M, Korn S, et al. Efficacy of tiotropium plus olodaterol in patients with chronic obstructive pulmonary disease by initial disease severity and treatment intensity: a post hoc analysis. Adv Ther. 2015;32(6):523–36.Google Scholar
  20. 20.
    Maltais F, Buhl R, Koch A, et al. β-Blockers in COPD: a cohort study from the TONADO research program. Chest. 2018;153(6):1315–25.Google Scholar
  21. 21.
    Buhl R, Derom E, Bjermer L, et al. Tiotropium + olodaterol in patients with moderate to severe COPD with chronic bronchitis and/or emphysema [abstract no. PA979]. Eur Respir J. 2016;48(Suppl 60).Google Scholar
  22. 22.
    Singh D, Gaga M, Schmidt O, et al. Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies. Respir Res. 2016;17:73.Google Scholar
  23. 23.
    Martinez FJ, Abrahams RA, Ferguson GT, et al. Effects of baseline symptom burden on treatment response in COPD. Int J Chron Obstruct Pulmon Dis. 2019;14:181–94.Google Scholar
  24. 24.
    Derom E, Beeh KM, Echave-Sustaeta J, et al. Tiotropium + olodaterol provides significant lung-function benefits compared to flucticasone + salmeterol regardless of prior bronchodilator use [abstract no. PA978]. Eur Respir J. 2017;48(Suppl 60).Google Scholar
  25. 25.
    Ferguson GT, Karpel J, Bennett N, et al. Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies. NPJ Prim Care Respir Med. 2017;27(1):7.Google Scholar
  26. 26.
    Bai C, Ichinose M, Lee SH, et al. Lung function and long-term safety of tiotropium/olodaterol in East Asian patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2017;12:3329–39.Google Scholar
  27. 27.
    Ichinose M, Taniguchi H, Takizawa A, et al. The efficacy and safety of combined tiotropium and olodaterol via the Respimat® inhaler in patients with COPD: results from the Japanese sub-population of the Tonado® studies. Int J Chron Obstruct Pulmon Dis. 2016;11(1):2017–27.Google Scholar
  28. 28.
    Ichinose M, Nishimura M, Akimoto M, et al. Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study. Int J Chron Obstruct Pulmon Dis. 2018;13:2147–56.Google Scholar
  29. 29.
    Ichinose M, Minakata Y, Motegi T, et al. Efficacy of tiotropium/olodaterol on lung volume, exercise capacity, and physical activity. Int J Chron Obstruct Pulmon Dis. 2018;13:1407–19.Google Scholar
  30. 30.
    Minakata Y, Motegi T, Ueki J, et al. Efficacy of tiotropium/olodaterol on sedentary/active time in COPD patients: VESUTO study [abstract no. PA4390]. Eur Respir J. 2018;52(Suppl 62).Google Scholar
  31. 31.
    Feldman GJ, Sousa AR, Lipson DA, et al. Comparative efficacy of once-daily umeclidinium/vilanterol and tiotropium/olodaterol therapy in symptomatic chronic obstructive pulmonary disease: a randomized study. Adv Ther. 2017;34(11):2518–33.Google Scholar
  32. 32.
    Valipour A, Tamm M, Kocianova J, et al. Improvement of self-reported physical functioning with tiotropium/olodaterol in Central and Eastern European COPD patients [abstract no. PA912]. Eur Respir J. 2018;52.Google Scholar
  33. 33.
    Buhl R, Magder S, Bothner U, et al. Long-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease. Respir Med. 2017;122:58–66.Google Scholar
  34. 34.
    Ferguson GT, Buhl R, Bothner U, et al. Safety of tiotropium/olodaterol in chronic obstructive pulmonary disease: pooled analysis of three large, 52-week, randomized clinical trials. Respir Med. 2018;143:67–73.Google Scholar
  35. 35.
    Ichinose M, Kato M, Takizawa A, et al. Long-term safety and efficacy of combined tiotropium and olodaterol in Japanese patients with chronic obstructive pulmonary disease. Respir Investig. 2017;55(2):121–9.Google Scholar
  36. 36.
    Singh D. New combination bronchodilators for chronic obstructive pulmonary disease: current evidence and future perspectives. Br J Clin Pharmacol. 2015;79(5):695–708.Google Scholar
  37. 37.
    Calzetta L, Rogliani P, Matera MG, et al. A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD. Chest. 2016;149(5):1181–96.Google Scholar
  38. 38.
    Schlueter M, Gonzalez-Rojas N, Baldwin M, et al. Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting beta2-agonists: a systematic review and network meta-analysis. Ther Adv Respir Dis. 2016;10(2):89–104.Google Scholar
  39. 39.
    Sion KYJ, Huisman EL, Punekar YS, et al. A network meta-analysis of long-acting muscarinic antagonist (LAMA) and long-acting β2-agonist (LABA) combinations in COPD. Pulm Ther. 2017;3:297–316.Google Scholar
  40. 40.
    Rogliani P, Matera MG, Ora J, et al. The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis. Int J Chron Obstruct Pulmon Dis. 2017;12:3469–85.Google Scholar
  41. 41.
    Molimard M, Raherison C, Lignot S, et al. Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients. Eur Respir J. 2017;49(2):1601794.Google Scholar
  42. 42.
    Dalby RN, Eicher J, Zierenberg B. Development of Respimat® Soft Mist™ Inhaler and its clinical utility in respiratory disorders. Med Devices (Auckl). 2011;4:145–55.Google Scholar
  43. 43.
    Dekhuijzen PN, Lavorini F, Usmani OS. Patients’ perspectives and preferences in the choice of inhalers: the case for Respimat® or HandiHaler®. Patient Prefer Adherence. 2016;10:1561–72.Google Scholar
  44. 44.
    Oliveira MVC, Pizzichini E, da Costa CH, et al. Evaluation of the preference, satisfaction and correct use of Breezhaler® and Respimat® inhalers in patients with chronic obstructive pulmonary disease—INHALATOR study. Respir Med. 2018;144:61–7.Google Scholar
  45. 45.
    Asakura Y, Nishimura N, Maezawa K, et al. Effect of switching tiotropium HandiHaler® to Respimat® Soft Mist Inhaler in patients with COPD: the difference of adverse events and usability between inhaler devices. J Aerosol Med Pulm Drug Deliv. 2013;26(1):41–5.Google Scholar
  46. 46.
    Miravitlles M, Montero-Caballero J, Richard F, et al. A cross-sectional study to assess inhalation device handling and patient satisfaction in COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:407–15.Google Scholar
  47. 47.
    Dhand R, Eicher J, Hansel M, et al. Improving usability and maintaining performance: human-factor and aerosol-performance studies evaluating the new reusable Respimat inhaler. Int J Chron Obstruct Pulmon Dis. 2019;14:509–23.Google Scholar
  48. 48.
    Tebboth A, Ternouth A, Gonzalez-Rojas N. UK-specific cost-effectiveness of tiotropium + olodaterol fixed-dose combination versus other LAMA + LABA combinations in patients with COPD. Clinicoecon Outcomes Res. 2016;8:667–74.Google Scholar
  49. 49.
    Hoogendoorn M, Corro Ramos I, Baldwin M, et al. Long-term cost-effectiveness of the fixed-dose combination of tiotropium plus olodaterol based on the DYNAGITO trial results. Int J Chron Obstruct Pulmon Dis. 2019;14:447–56.Google Scholar
  50. 50.
    Selya-Hammer C, Gonzalez-Rojas Guix N, Baldwin M, et al. Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy. Ther Adv Respir Dis. 2016;10(5):391–401.Google Scholar
  51. 51.
    van Boven JF, Kocks JW, Postma MJ. Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium-olodaterol for patients with COPD in the Netherlands. Int J Chron Obstruct Pulmon Dis. 2016;11(1):2191–201.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Springer NatureAucklandNew Zealand

Personalised recommendations